Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Monograph series

Immune modulators

Thymic peptides, host-defence peptides and undefined thymic extracts.

Monographs in this series

3 documents
  • CEI-MN-042Immune modulatorsUnapproved, research supply2 assessed outcomesversion 4.3

    LL-37 permeabilises bacterial membranes through an amphipathic helical mechanism and separately acts as a chemoattractant and immunomodulator through formyl peptide receptor 2. It also promotes angiogenesis and wound…

    Low27 Apr 2026
  • CEI-MN-041Immune modulatorsApproved2 assessed outcomesversion 4.1

    Thymalin is a fractionated calf-thymus extract registered in the Russian Federation as an immunomodulator. Because its composition is not defined, no mechanism can be stated at molecular level, and batch-to-batch consistency is…

    Very low15 Jul 2026
  • CEI-MN-040Immune modulatorsApproved2 assessed outcomesversion 4.2

    Thymosin alpha-1 promotes T-lymphocyte differentiation and maturation, increases interleukin-2 and interferon-gamma production, and enhances dendritic-cell function. Its clinical applications exploit immune reconstitution rather…

    Moderate23 Jan 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.